NA-931

Description

What is NA-931 Peptide?

NA-931, also referred to by the investigational name Bioglutide, is a first-in-class orally active small-molecule investigational compound derived from a cyclic metabolite fragment of insulin-like growth factor 1 (IGF-1). 

It is classified as a quadruple receptor agonist and is studied in controlled research settings for its capacity to simultaneously engage four distinct G protein-coupled receptor pathways. 

The pathways are believed to be involved in metabolic regulation. The names of these pathways are 

• IGF-1 receptor (IGF-1R)
• Glucagon-like peptide-1 receptor (GLP-1R)
• Glucose-dependent insulinotropic polypeptide receptor (GIPR), 
•  Glucagon receptor (GCGR).

 

Compound Name	NA-931 (Bioglutide)
Classification	First-in-class oral small-molecule quadruple receptor agonist; cyclic IGF-1 metabolite fragment-derived
CAS Number	Proprietary – not publicly disclosed
Molecular Formula	Proprietary – not publicly disclosed
Molecular Weight	Proprietary – not publicly disclosed
PubChem CID	Not publicly assigned as of June 2026
Physical Form	Lyophilized powder
Solubility	Orally bioavailable; lipophilic cyclic small-molecule structure
Storage	−20°C lyophilized, protected from light and moisture
Research Transparency	Full structural identity is proprietary (Biomed Industries, Inc.) and not independently published in peer-reviewed literature as of June 2026. Properties reflect class-level and manufacturer-reported characteristics only.
WADA Status	Not listed on WADA 2026 Prohibited List. Verify via GlobalDRO.com prior to sport science research use.
Classification (Regulatory)	Research Use Only (RUO)

 

How Does NA-931 Peptide Work?

NA-931 peptide operates through simultaneous agonism at four metabolic receptor systems, each coupled to distinct intracellular signaling cascades. 

Preclinical and Phase 2-completed investigational data suggest the compound engages GLP-1R and GIPR via adenylyl cyclase activation, elevating intracellular cyclic AMP (cAMP) concentrations to modulate insulin secretory signaling in receptor-expressing cell systems. 

Concurrent activation of the glucagon receptor (GCGR) is hypothesized to stimulate hepatic and adipose energy expenditure pathways through PKA-dependent phosphorylation cascades.

Engagement of the IGF-1 receptor initiates PI3K/Akt and MAPK/ERK signaling, pathways associated with protein synthesis regulation and cellular anabolic processes in skeletal muscle cell preparations. 

Investigators propose that the coordinated activation of all four receptor systems generates a homeostatic regulatory effect across glucose, lipid, and energy metabolism circuits that is mechanistically distinct from single- or dual-receptor agonists currently under investigation.

Phase 2 Clinical Investigation Summary

Phase 2 randomized, double-blind, placebo-controlled 13-week study (NCT06564753) demonstrated dose-dependent body weight reductions of up to 14.8% from baseline at 150mg daily, or approximately 13.2% relative to placebo, in participants with obesity or overweight plus comorbidities. No clinically significant muscle loss was observed. The compound has been advanced to Phase 3 investigation. 

[Tran, L.L. 2025, Diabetes 74 Supplement 1, 143-OR – cited for receptor pharmacology context only; documents human clinical research and does not apply to the research-grade formulation supplied here.] 

What are the Potential Research Applications of the NA-931 Peptide?

In controlled laboratory and investigational settings, researchers study the NA-931 peptide for the following potential applications.

• Modulates quadruple receptor-mediated metabolic signaling across IGF-1R, GLP-1R, GIPR, and GCGR pathways in receptor-expression assay systems
• Investigates cAMP-dependent insulin secretory signaling via GLP-1R and GIPR activation in pancreatic cell research models
• Examines IGF-1R-linked PI3K/Akt pathway activity associated with skeletal muscle protein synthesis regulation in myocyte preparations
• Supports investigation of glucagon receptor-mediated hepatic energy expenditure signaling in liver cell research systems
• Facilitates the study of multi-receptor homeostatic modulation of glucose and lipid metabolism parameters in metabolic research frameworks

What are the Potential Observed Variables of NA-931 Peptide?

Investigators in early-phase research settings have noted the following parameters associated with NA-931. Long-term comprehensive studies remain necessary to fully characterize the safety profile of this investigational compound.

• Mild gastrointestinal signaling variables, including transient nausea-associated pathway activation, were observed at higher investigational concentrations
• Potential modulation of glucagon receptor-mediated cardiovascular signaling parameters
• Possible influence on IGF-1R-linked growth factor signaling that warrants monitoring in prolonged investigational protocols
• Transient alterations in glucose homeostasis parameters noted in early-phase concentration-response assessments
• Risk of off-target receptor cross-reactivity requiring characterization across extended research timelines

Where to Buy NA-931 Peptide?

If you are planning to purchase the NA-931 peptide for laboratory research, source it from RCDbio. Our online shop provides third-party tested, research-grade NA-931 peptide meeting rigorous purity standards. We offer secure transaction methods to protect researchers’ privacy and provide expedited delivery of all research compounds.

FAQs

What distinguishes NA-931’s receptor binding profile from dual-agonist peptides?

Unlike dual-agonist compounds targeting GLP-1R and GIPR alone, NA-931 incorporates concurrent IGF-1R and GCGR agonism within a single molecular scaffold. This quadruple engagement produces non-redundant downstream signaling — IGF-1R-linked PI3K/Akt activity operates independently of cAMP cascades initiated by GLP-1R and GIPR. Researchers investigating multi-receptor crosstalk may find NA-931 a mechanistically valuable tool compound for dissecting how simultaneous receptor co-activation influences downstream effector competition at the cellular level.

What are the recommended storage and handling conditions for NA-931?

NA-931 in lyophilized form should be stored at −20°C, protected from light and repeated freeze-thaw cycling to maintain compound integrity. Upon reconstitution, short-term storage at 4°C is recommended for up to 2 weeks; long-term aliquots should be returned to −20°C immediately. Researchers are advised to consult the compound’s Safety Data Sheet (SDS) prior to handling and to follow institutional biosafety protocols applicable to investigational small-molecule peptides.

What parameters should researchers monitor when studying NA-931?

Researchers are advised to establish orthogonal endpoint panels covering cAMP accumulation (GLP-1R/GIPR/GCGR), Akt and ERK phosphorylation (IGF-1R), and downstream transcriptional markers per pathway. Dose-titration protocols should incorporate interval washout periods to distinguish acute receptor saturation effects from sustained downstream signaling. Baseline receptor expression profiling of the cell system used is strongly recommended prior to initiating NA-931 exposure.

How does IGF-1R co-activation in NA-931’s mechanism inform muscle preservation?

IGF-1R engagement activates the PI3K/Akt/mTOR axis, a cascade associated with skeletal muscle protein synthesis and suppression of ubiquitin-proteasome-mediated protein degradation in myocyte preparations. Unlike GLP-1-only compounds, where caloric deficit-driven muscle catabolism is an observed variable, early-phase NA-931 data indicate preservation of lean mass parameters alongside body weight reduction endpoints. Researchers studying body composition mechanisms may find NA-931 a useful comparator for isolating IGF-1R-mediated anabolic contributions in multi-receptor metabolic models.

Disclaimer

NA-931 peptide is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, or cure any disease. 

The Food and Drug Administration has not evaluated the statements on our website. Research must comply with applicable IRB or IACUC guidelines where relevant to the experimental protocol. By purchasing, you agree to our Terms and Conditions. In addition, RCDbio reserves the right to refuse sales to unauthorized individuals.

For queries, complaints, or support, contact support@rcdbio.co

Reference Links

Tran, L. L. (2025). Phase 1 clinical trials results of NA-931, a novel quadruple IGF-1, GLP-1, GIP, and glucagon receptor agonist for the treatment of obesity. Endocrine Practice. https://www.endocrinepractice.org/article/S1530-891X(25)00637-8/fulltext

Tran, L. L. (2025). 143-OR: NA-931, a novel quadruple IGF-1, GLP-1, GIP, and glucagon receptor agonist reduces body weight without muscle loss. Diabetes, 74(Supplement 1). https://diabetesjournals.org/diabetes/article/74/Supplement_1/143-OR/159475

Tran, L. L. (2025). 2189-LB: Phase 2 clinical trials of NA-931 to study subjects who are obese with at least one weight-related comorbid condition. Diabetes, 74(Supplement 1). https://diabetesjournals.org/diabetes/article/74/Supplement_1/2189-LB/160162

National Institutes of Health, U.S. National Library of Medicine. (2024). Study of NA-931 in subjects who are obese or overweight with weight-related comorbid conditions (NCT06564753). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06564753

National Institutes of Health, U.S. National Library of Medicine. (2024). Safety and tolerability of NA-931 in overweight or obese adults (NCT06615700). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06615700